Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: InMed Pharmaceuticals Inc. INM

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release FY 2021 Financial Report, Acquire BayMedia

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that it will release its fiscal year 2021 financial report at the end of the week. INM’s full financial statements and related MD&A … Continue reading

Posted in InMed Pharmaceuticals Inc. INM, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Slated to Participate in Tribe Public Webinar

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that its CEO Eric A. Adams will be a featured presenter at Tribe Public’s upcoming complimentary ZOOM presentation titled “Accelerating The Commercialization of … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc.BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoidsUpon closing, the transaction will make InMed a global leader in … Continue reading

Posted in InMed Pharmaceuticals Inc. INM, Small Cap News | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Definitive Agreement for ‘Transformative’ Acquisition of Leading Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has signed a definitive agreement to acquire BayMedica Inc., a private, U.S.-based company that specializes in the manufacturing and commercialization of rare cannabinoids. According to … Continue reading

Posted in InMed Pharmaceuticals Inc. INM, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Slated for Live Webcast at VirtualInvestorConferences.com

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be featured at the upcoming VirtualInvestorConferences.com. InMed president and CEO is scheduled to present … Continue reading

Posted in InMed Pharmaceuticals Inc. INM, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Cannabis Investor Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be a featured company in the upcoming Cannabis Industry Virtual Investor Conference, slated for … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucomaInMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plantsIn … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoidsInMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sourcesIntegraSyn’s ability to … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Collaborate to Build Leading Rare Cannabinoid Company

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is creating a pipeline of drug candidates to treat various diseases with high unmet medical needs. “In a … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright Ophthalmology Virtual Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced its plans to participate at the upcoming H.C. Wainwright Ophthalmology Virtual Conference. According to the update, InMed’s … Continue reading

Posted in InMed Pharmaceuticals Inc. INM, MissionIRNewsBreaks | Leave a comment